The U.S. Food and Drug Administration (FDA) recently approved the use of Teplizumab, a new, immunotherapy drug that has been shown to delay the onset of type 1 diabetes by at least two years. The drug ...

Immunologist and UCSF Professor Emeritus Jeffrey Bluestone, PhD, has been elected to the National Academy of Sciences (NAS) – one of the highest honors bestowed on American scientists. Bluestone was ...

Diagnosed with diabetes at 12-years-old, Maureen McGrath knows first-hand how devastating the disease can be. As a clinical professor at UCSF, she's now devoting her career to helping others get the ...

SAN FRANCISCO, Sep 26, 2011 (BUSINESS WIRE) -- A new interactive mobile phone app called DiabetesIQ, released this week, challenges people to test their knowledge of diabetes and to compete with one ...

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors. The intent ...

The University of California, San Francisco (UCSF) has signed an alliance with international pharmaceutical company Sanofi (EURONEXT: SAN and NYSE: SNY) to share expertise in diabetes research and ...

UC Berkeley’s College of Computing, Data Science and Society, or CDSS, launched the Agile Metabolic Health project earlier this month in partnership with UCSF to improve the treatment of diabetes and ...

UCSF researchers have for the first time transformed human stem cells into mature insulin-producing cells, a major breakthrough in the effort to develop a cure for Type 1 diabetes. Matthias Hebrok, Ph ...

To live with type 1 diabetes is to be ruled by relentless routine. Food must be carefully monitored, and the only treatment, subcutaneous insulin, is burdensome—requiring regular injections or an ...

The University of California, San Francisco (UCSF) has signed an alliance with international pharmaceutical company Sanofi (EURONEXT: SAN and NYSE: SNY) to share expertise in diabetes research and ...